These innovative agents represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose levels. https://montyzsnd104717.fitnell.com/79951379/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide